A Daily Multivitamin May Slightly Slow Rates of Ageing

Why It Matters

The modest slowing of epigenetic aging suggests multivitamins could offer a low‑risk, incremental health benefit for older adults, potentially influencing preventive care strategies.

Key Takeaways

• Randomized trial: 1,000 seniors took multivitamin or placebo.
• Epigenetic clocks showed ~4 months slower aging over two years.
• Significant effects only on second‑generation clocks, modest size.
• No adverse effects observed; benefits minimal.
• Findings limited to European‑descent older adults.

Pulse Analysis

The debate over multivitamins has long been clouded by observational studies that cannot untangle cause and effect. This new trial, led by Harvard’s Howard Sesso, stands out because it employed a double‑blind, placebo‑controlled design with a thousand participants around the age of seventy. By measuring DNA methylation patterns—so‑called epigenetic clocks—the researchers tapped into a biomarker that tracks biological age more precisely than chronological years. Such rigorous methodology provides a clearer window into how everyday supplements might interact with the aging process.

Results showed the multivitamin group’s epigenetic age progressed roughly four months slower over two years, a difference that reached statistical significance on the newer, second‑generation clocks linked to health decline and mortality risk. While the magnitude is modest, the absence of any detected side effects reinforces the safety profile of standard‑dose formulas like Centrum Silver. Critics caution that a four‑month shift does not automatically translate into measurable health improvements, and the study’s focus on participants of European ancestry limits broader applicability.

For the supplement industry, these findings could bolster marketing narratives that position multivitamins as a preventive tool for seniors, albeit with a tempered claim of “slight aging slowdown.” Clinicians may consider recommending a daily multivitamin to older patients who lack nutrient gaps, especially when vitamin D supplementation is already advised in winter months. Future research should explore longer follow‑up periods, diverse populations, and dose variations to determine whether the observed epigenetic benefit persists and eventually impacts morbidity or lifespan.